This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Chemotherapy Remove Generic Medicine Remove Hospitals Related Topics
FDA More Related Topics >
article thumbnail

CHMP meeting highlights: April 2024

European Pharmaceutical Review

APRIL 30, 2024

If approved, fruquintinib could provide a new oral, chemotherapy-free option as the first and only selective inhibitor of all three vascular endothelial growth factor receptors (VEGFR) receptors approved in the EU for this disease, according to Takeda. This covers paediatric plaque psoriasis, psoriatic arthritis and Crohn’s disease.

Generic Medicine 91
Generic Medicine Chemotherapy Hospitals FDA 91
article thumbnail

CHMP meeting highlights: January 2024

European Pharmaceutical Review

JANUARY 30, 2024

The CHMP recommended Exblifep (cefepime/enmetazobactam) as a treatment for complicated urinary tract infections, including pyelonephritis, hospital-acquired pneumonia, including ventilator associated pneumonia, and for treating bacteraemia caused by the aforementioned infections.

Generic Medicine 96
Generic Medicine Chemotherapy Hospitals 96
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 18,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024